Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

ATM loss in NSCLC increases sensitivity to cisplatin and PARP inhibition.

Bebb DG, Petersen LF, Moore J, Elegbede A, Lees-Miller S.

Ann Oncol. 2019 Feb;30 Suppl 1:i6. doi: 10.1093/annonc/mdz029.008. Epub 2020 Jan 8. No abstract available.

2.

Real-World Adherence to Guideline-Recommended Treatment for Small Cell Lung Cancer.

Elegbede AA, Gibson AJ, Fu H, Dean ML, Ezeife DA, Lau H, Cheung WY, Bebb DG.

Am J Clin Oncol. 2019 Dec 10. doi: 10.1097/COC.0000000000000657. [Epub ahead of print]

PMID:
31842113
3.

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors.

Meyers DE, Stukalin I, Vallerand IA, Lewinson RT, Suo A, Dean M, North S, Pabani A, Cheng T, Heng DYC, Bebb DG, Morris DG.

Cancers (Basel). 2019 Nov 2;11(11). pii: E1713. doi: 10.3390/cancers11111713.

4.

Crizotinib inhibition of ROS1-positive tumours in advanced non-small-cell lung cancer: a Canadian perspective.

Bebb DG, Agulnik J, Albadine R, Banerji S, Bigras G, Butts C, Couture C, Cutz JC, Desmeules P, Ionescu DN, Leighl NB, Melosky B, Morzycki W, Rashid-Kolvear F, Lab C, Sekhon HS, Smith AC, Stockley TL, Torlakovic E, Xu Z, Tsao MS.

Curr Oncol. 2019 Aug;26(4):e551-e557. doi: 10.3747/co.26.5137. Epub 2019 Aug 1.

5.

Impact of Asian ethnicity on outcome in metastatic EGFR-mutant non-small cell lung cancer.

Gibson AJW, D'Silva A, Elegbede AA, Tudor RA, Dean ML, Bebb DG, Hao D.

Asia Pac J Clin Oncol. 2019 Dec;15(6):343-352. doi: 10.1111/ajco.13234. Epub 2019 Sep 4.

PMID:
31486229
6.

Combined poly-ADP ribose polymerase and ataxia-telangiectasia mutated/Rad3-related inhibition targets ataxia-telangiectasia mutated-deficient lung cancer cells.

Jette NR, Radhamani S, Arthur G, Ye R, Goutam S, Bolyos A, Petersen LF, Bose P, Bebb DG, Lees-Miller SP.

Br J Cancer. 2019 Oct;121(7):600-610. doi: 10.1038/s41416-019-0565-8. Epub 2019 Sep 4.

PMID:
31481733
7.

Factors associated with early mortality in non-small cell lung cancer patients following systemic anti-cancer therapy: A 10 year population-based study.

Gibson AJW, Li H, D'Silva A, Elegbede AA, Tudor RA, Otsuka S, Bebb DG, Cheung WY.

Lung Cancer. 2019 Aug;134:141-146. doi: 10.1016/j.lungcan.2019.06.003. Epub 2019 Jun 6.

PMID:
31319972
8.

Canadian perspectives: update on inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Cheema P, Agulnik J, Albadine R, Bebb DG, Blais N, Burkes R, Butts C, Card PB, Chan AMY, Hirsh V, Ionescu DN, Juergens R, Morzycki W, Poonja Z, Sangha R, Tehfe M, Tsao MS, Vincent M, Xu Z, Liu G.

Curr Oncol. 2018 Oct;25(5):317-328. doi: 10.3747/co.25.4379. Epub 2018 Oct 31. Review.

9.

Comparison of Clinical Characteristics and Outcomes in Relapsed Versus De Novo Metastatic Non-Small Cell Lung Cancer.

Gibson AJW, Li H, D'Silva A, Tudor RA, Elegbede AA, Otsuka S, Bebb DG, Cheung WY.

Am J Clin Oncol. 2019 Jan;42(1):75-81. doi: 10.1097/COC.0000000000000483.

PMID:
30211724
10.

Impact of number versus location of metastases on survival in stage IV M1b non-small cell lung cancer.

Gibson AJW, Li H, D'Silva A, Tudor RA, Elegbede AA, Otsuka SM, Bebb DG, Cheung WY.

Med Oncol. 2018 Aug 2;35(9):117. doi: 10.1007/s12032-018-1182-8.

PMID:
30073425
11.

Associations of objectively assessed physical activity and sedentary time with health-related quality of life among lung cancer survivors: A quantile regression approach.

D'Silva A, Gardiner PA, Boyle T, Bebb DG, Johnson ST, Vallance JK.

Lung Cancer. 2018 May;119:78-84. doi: 10.1016/j.lungcan.2018.03.010. Epub 2018 Mar 10.

PMID:
29656757
12.

Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011.

Ko JJ, Tudor R, Li H, Liu M, Skolnik K, Boland WK, Macklow J, Morris D, Bebb DG.

Curr Oncol. 2017 Dec;24(6):e486-e493. doi: 10.3747/co.24.3691. Epub 2017 Dec 20.

13.

Beyond disease-progression: Clinical outcomes after EGFR-TKIs in a cohort of EGFR mutated NSCLC patients.

Tudor RA, D'Silva A, Tremblay A, MacEachern P, Morris D, Brenner D, Kopciuk K, Bebb DG.

PLoS One. 2017 Aug 4;12(8):e0181867. doi: 10.1371/journal.pone.0181867. eCollection 2017.

14.

Loss of tumour-specific ATM protein expression is an independent prognostic factor in early resected NSCLC.

Petersen LF, Klimowicz AC, Otsuka S, Elegbede AA, Petrillo SK, Williamson T, Williamson CT, Konno M, Lees-Miller SP, Hao D, Morris D, Magliocco AM, Bebb DG.

Oncotarget. 2017 Jun 13;8(24):38326-38336. doi: 10.18632/oncotarget.16215.

15.

ATM-Deficient Colorectal Cancer Cells Are Sensitive to the PARP Inhibitor Olaparib.

Wang C, Jette N, Moussienko D, Bebb DG, Lees-Miller SP.

Transl Oncol. 2017 Apr;10(2):190-196. doi: 10.1016/j.tranon.2017.01.007. Epub 2017 Feb 6.

16.

Canadian consensus: inhibition of ALK-positive tumours in advanced non-small-cell lung cancer.

Melosky B, Agulnik J, Albadine R, Banerji S, Bebb DG, Bethune D, Blais N, Butts C, Cheema P, Cheung P, Cohen V, Deschenes J, Ionescu DN, Juergens R, Kamel-Reid S, Laurie SA, Liu G, Morzycki W, Tsao MS, Xu Z, Hirsh V.

Curr Oncol. 2016 Jun;23(3):196-200. doi: 10.3747/co.23.3120. Epub 2016 Jun 9.

17.

Temporal characterization of serum metabolite signatures in lung cancer patients undergoing treatment.

Hao D, Sarfaraz MO, Farshidfar F, Bebb DG, Lee CY, Card CM, David M, Weljie AM.

Metabolomics. 2016;12:58. doi: 10.1007/s11306-016-0961-5. Epub 2016 Feb 27.

18.

Exercise preferences, levels and quality of life in lung cancer survivors.

Leach HJ, Devonish JA, Bebb DG, Krenz KA, Culos-Reed SN.

Support Care Cancer. 2015 Nov;23(11):3239-47. doi: 10.1007/s00520-015-2717-6. Epub 2015 Apr 2.

PMID:
25832895
19.

Digital differentiation of non-small cell carcinomas of the lung by the fractal dimension of their epithelial architecture.

Lee LH, Tambasco M, Otsuka S, Wright A, Klimowicz A, Petrillo S, Morris D, Magliocco A, Bebb DG.

Micron. 2014 Dec;67:125-131. doi: 10.1016/j.micron.2014.07.005. Epub 2014 Jul 28.

PMID:
25151215
20.

Low ATM protein expression and depletion of p53 correlates with olaparib sensitivity in gastric cancer cell lines.

Kubota E, Williamson CT, Ye R, Elegbede A, Peterson L, Lees-Miller SP, Bebb DG.

Cell Cycle. 2014;13(13):2129-37. doi: 10.4161/cc.29212. Epub 2014 May 19.

21.

Predicting PARP inhibitor sensitivity and resistance.

Bebb DG, Lees-Miller SP.

Cell Cycle. 2012 Nov 15;11(22):4110. doi: 10.4161/cc.22604. Epub 2012 Oct 25. No abstract available.

22.

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53.

Williamson CT, Kubota E, Hamill JD, Klimowicz A, Ye R, Muzik H, Dean M, Tu L, Gilley D, Magliocco AM, McKay BC, Bebb DG, Lees-Miller SP.

EMBO Mol Med. 2012 Jun;4(6):515-27. doi: 10.1002/emmm.201200229. Epub 2012 Mar 13.

23.

CXCR4 overexpression is associated with poor outcome in females diagnosed with stage IV non-small cell lung cancer.

Otsuka S, Klimowicz AC, Kopciuk K, Petrillo SK, Konno M, Hao D, Muzik H, Stolte E, Boland W, Morris D, Magliocco AM, Bebb DG.

J Thorac Oncol. 2011 Jul;6(7):1169-78. doi: 10.1097/JTO.0b013e3182199a99.

24.

The viral tropism of two distinct oncolytic viruses, reovirus and myxoma virus, is modulated by cellular tumor suppressor gene status.

Kim M, Williamson CT, Prudhomme J, Bebb DG, Riabowol K, Lee PW, Lees-Miller SP, Mori Y, Rahman MM, McFadden G, Johnston RN.

Oncogene. 2010 Jul 8;29(27):3990-6. doi: 10.1038/onc.2010.137. Epub 2010 May 17.

25.

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors.

Williamson CT, Muzik H, Turhan AG, Zamò A, O'Connor MJ, Bebb DG, Lees-Miller SP.

Mol Cancer Ther. 2010 Feb;9(2):347-57. doi: 10.1158/1535-7163.MCT-09-0872. Epub 2010 Feb 2.

26.

Physical activity and diet behaviour in colorectal cancer patients receiving chemotherapy: associations with quality of life.

Stephenson LE, Bebb DG, Reimer RA, Culos-Reed SN.

BMC Gastroenterol. 2009 Jul 27;9:60. doi: 10.1186/1471-230X-9-60.

27.

Radiation induced apoptosis in ataxia telangiectasia homozygote, heterozygote and normal cells.

Bebb DG, Warrington PJ, de Jong G, Yu Z, Moffat JA, Skov K, Spacey S, Gelmon K, Glickman BW.

Mutat Res. 2001 May 9;476(1-2):13-20.

PMID:
11336979
28.

Absence of mutations in the ATM gene in forty-seven cases of sporadic breast cancer.

Bebb DG, Yu Z, Chen J, Telatar M, Gelmon K, Phillips N, Gatti RA, Glickman BW.

Br J Cancer. 1999 Aug;80(12):1979-81.

29.

Caffeine does not potentiate gamma-radiation induced DNA damage in ataxia telangiectasia lymphoblastoid cells.

Bebb DG, Steele PP, Warrington PJ, Moffat JA, Glickman BW.

Mutat Res. 1998 Jun 5;401(1-2):27-32.

PMID:
9639667

Supplemental Content

Support Center